Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding series E warrants to purchase up to an aggregate of 3,216,928 of the Company’s ordinary shares originally issued in August 2026 having a reduced exercise price of $0.2603 per share. The ordinary shares issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (File No. 333-298137). The gross proceeds to the Company from the exercise of the warrants are expected to be $837,366.36, prior to deducting placement agent fees and estimated offering expenses. The offering is expected to close on or about September 29, 2026, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering as working capital for general corporate purposes.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

In consideration for the immediate exercise of the warrants for cash, the Company will issue new unregistered Series F warrants to purchase up to 3,216,928 of the Company’s ordinary shares and new unregistered Series G warrants to purchase up to 3,216,928 of the Company’s ordinary shares. The new warrants will have an exercise price of $0.2603 per share and will be exercisable upon the effective date of the increase of the Company’s authorized ordinary shares following shareholder approval (the "Authorized Share Increase Date"). The Series F new warrants will expire five years after the later of (i) the Authorized Share Increase Date and (ii) the effective date of the Resale Registration Statement (as defined below) and the Series G new warrants will expire twenty-four months after the later of (x) the Authorized Share Increase Date and (y) the effective date of the Resale Registration Statement.